Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 Mar 24

PMID 35323372

Authors

Lauren Clarfield

Laura Diamond

Michelle Jacobson

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility Gene 2 (BRCA 2) germline mutations confer an estimated 20 to 40 times increased risk of OC when compared to the general population. The majority of BRCA-associated OC is identified in the late stage, and no effective screening method has been proven to reduce mortality. Several pharmacologic and surgical options exist for risk-reduction of gynecologic malignancy in BRCA 1/2 mutation carriers. This review summarizes up-to-date research on pharmacologic risk-reducing interventions, including the oral contraceptive pill, acetylsalicylic acid/nonsteroidal anti inflammatory drugs (ASA/NSAID) therapy, and denosumab, and surgical risk-reducing interventions, including risk-reducing bilateral salpingo-oophorectomy, salpingectomy with delayed oophorectomy, and hysterectomy at the time of risk-reducing bilateral salpingo-oophorectomy.

Citing Articles

Clinical characterization and genomic landscape of gynecological cancers among patients attending a Chinese hospital.

Jiang C, Lu Y, Liu H, Cai G, Peng Z, Feng W Front Oncol. 2023; 13:1143876.

PMID: 37064128 PMC: 10101327. DOI: 10.3389/fonc.2023.1143876.

Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review.

Bertozzi S, Londero A, Xholli A, Azioni G, Di Vora R, Paudice M J Clin Med. 2023; 12(4).

PMID: 36835955 PMC: 9967164. DOI: 10.3390/jcm12041422.

Snail Promotes Cancer Cell Proliferation via Its Interaction with the BIRC3.

Rho S, Byun H, Kim B, Lee C Biomol Ther (Seoul). 2022; 30(4):380-388.

PMID: 35711139 PMC: 9252879. DOI: 10.4062/biomolther.2022.063.

References

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Balayla J, Gil Y, Lasry A, Mitric C . Ever-use of the intra-uterine device and the risk of ovarian cancer. J Obstet Gynaecol. 2020; 41(6):848-853. DOI: 10.1080/01443615.2020.1789960. View

Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U . Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345(4):235-40. DOI: 10.1056/NEJM200107263450401. View

Park B, Hopper J, Win A, Dowty J, Sung H, Ahn C . Reproductive factors as risk modifiers of breast cancer in mutation carriers and high-risk non-carriers. Oncotarget. 2017; 8(60):102110-102118. PMC: 5731939. DOI: 10.18632/oncotarget.22193. View

Beral V, DOLL R, Hermon C, Peto R, Reeves G . Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371(9609):303-14. DOI: 10.1016/S0140-6736(08)60167-1. View

Moorman P, Havrilesky L, Gierisch J, Coeytaux R, Lowery W, Urrutia R . Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013; 31(33):4188-98. DOI: 10.1200/JCO.2013.48.9021. View

van Leeuwen F, Benraadt J, Coebergh J, Kiemeney L, Gimbrere C, Otter R . Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994; 343(8895):448-52. DOI: 10.1016/s0140-6736(94)92692-1. View

Henderson J, Webber E, Sawaya G . Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018; 319(6):595-606. DOI: 10.1001/jama.2017.21421. View

Havrilesky L, Moss H, Chino J, Myers E, Kauff N . Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. Gynecol Oncol. 2017; 145(3):549-554. DOI: 10.1016/j.ygyno.2017.03.025. View

10.

Carter J, Pather S . An overview of uterine cancer and its management. Expert Rev Anticancer Ther. 2005; 6(1):33-42. DOI: 10.1586/14737140.6.1.33. View

11.

Steenbeek M, Harmsen M, Hoogerbrugge N, de Jong M, Maas A, Prins J . Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial. JAMA Oncol. 2021; 7(8):1203-1212. PMC: 8176392. DOI: 10.1001/jamaoncol.2021.1590. View

12.

Narod S, Dube M, Klijn J, Lubinski J, Lynch H, Ghadirian P . Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002; 94(23):1773-9. DOI: 10.1093/jnci/94.23.1773. View

13.

Schrijver L, Antoniou A, Olsson H, Mooij T, Roos-Blom M, Azarang L . Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol. 2021; 225(1):51.e1-51.e17. PMC: 8278569. DOI: 10.1016/j.ajog.2021.01.014. View

14.

Baandrup L, Kjaer S, Olsen J, Dehlendorff C, Friis S . Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann Oncol. 2014; 26(4):787-792. DOI: 10.1093/annonc/mdu578. View

15.

Cibula D, Zikan M, Dusek L, Majek O . Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011; 11(8):1197-207. DOI: 10.1586/era.11.38. View

16.

Iversen L, Fielding S, Lidegaard O, Morch L, Skovlund C, Hannaford P . Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ. 2018; 362:k3609. PMC: 6283376. DOI: 10.1136/bmj.k3609. View

17.

Carneiro V, Ramalho N . Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers. Int J Gynecol Cancer. 2021; 31(7):1096. DOI: 10.1136/ijgc-2021-002682. View

18.

Wheeler L, Desanto K, Teal S, Sheeder J, Guntupalli S . Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis. Obstet Gynecol. 2019; 134(4):791-800. DOI: 10.1097/AOG.0000000000003463. View

19.

Boerner T, Long Roche K . Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?. J Minim Invasive Gynecol. 2020; 28(3):403-408. PMC: 7954812. DOI: 10.1016/j.jmig.2020.09.020. View

20.

Gorodetska I, Kozeretska I, Dubrovska A . Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. J Cancer. 2019; 10(9):2109-2127. PMC: 6548160. DOI: 10.7150/jca.30410. View